Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective
| Autor: | Bianca M. Liederer, Edgar Schuck, Daniel R. Mudra, Jing Lin, Patricia Schroeder, Fan Wu, Harvey Wong, Cheng-Pang Hsu, Anu Shilpa Krishnatry, Haiqing Wang, Jerome T. Mettetal, Tonika Bohnert, Christopher R. Gibson, Alice Tsai, Marjoleen J.M.A Nijsen, Qiang Lu, Valeriu Damian-Iordache, Satyendra Suryawanshi, Patrick Trapa |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Drug medicine.medical_specialty Drug Industry media_common.quotation_subject Best practice Drug Evaluation Preclinical Pharmacology 030226 pharmacology & pharmacy Models Biological 03 medical and health sciences 0302 clinical medicine Drug Discovery medicine Animals Humans Intensive care medicine PK/PD models media_common Pharmaceutical industry Discussion group Pharmacokinetic pharmacodynamic business.industry Drug discovery 030104 developmental biology Drug development business |
| Zdroj: | Drug discovery today. 22(10) |
| ISSN: | 1878-5832 |
| Popis: | With inadequate efficacy being the primary cause for the attrition of drug candidates in clinical development, the need to better predict clinical efficacy earlier in the drug development process has increased in importance in the pharmaceutical industry. Here, we review current applications of translational pharmacokinetic-pharmacodynamic (PK-PD) modeling of preclinical data in the pharmaceutical industry, including best practices. Preclinical translational PK-PD modeling has been used in many therapeutic areas and has been impactful to drug development. The role of preclinical translational PK-PD modeling in drug discovery and development will continue to evolve and broaden, given that its broad implementation in the pharmaceutical industry is relatively recent and many opportunities still exist for its further application. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect